Company profile
Immunome Inc.
NASDAQ:IMNMBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Varegacestat | phase2_3 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06855264 | phase1 | completed | 2025-02-24 | 2025-04-08 | Immunome, Inc. | A Cardiac Liability Study of Varegacestat in Healthy Participants |
| NCT06845852 | phase1 | completed | 2025-02-25 | 2025-03-11 | Immunome, Inc. | A Phase 1 Mass Balance Study of Varegacestat |
| NCT07505771 | — | recruiting | 2026-06-19 | 2029-12-01 | Immunome, Inc. | A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer |
| NCT06823167 | phase1 | recruiting | 2025-02-26 | 2028-05-01 | Immunome, Inc. | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer |
| NCT07578571 | phase1 | recruiting | 2026-05-21 | 2029-01-01 | Immunome, Inc. | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer |
FDA applications (0)
No records yet.